Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.
Product Name : Ameile
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aumolertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : EQRx
Deal Size : Undisclosed
Deal Type : Collaboration
Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib
Details : Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).
Product Name : Ameile
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
July 23, 2020
Lead Product(s) : Aumolertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : EQRx
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
